Volume 2006, Issue 2

Abstract

To determine the prevalence of antibodies to HTLV-1 & II among the donor population in Qatar and to evaluate the relevance of continuing routine pretransfusion screening of all donations for HTLV-I& II we surveyed all the results of the screening tests performed on 124,266 donations collected in the period August 1991 to the end of January 2004. All donations were screened by ELISA based assays and all donors who tested positive were recalled for repeat ELISA testing and confirmatory testing by Western-Blot (WB). Two hundred and sixty nine donors tested positive for HTLV-I/HTLV-II antibodies by ELISA but only 81 donors could be retrieved for confirmatory testing. On repeat ELISA testing 27 donors gave negative reactions; the remaining 54 were still positive and were tested by WB. Of those, 22 were confirmed positive by WB, 20 were WB negative while the remaining 12 donors gave an indeterminate WB pattern. Only one of the 22 W-B confirmed positive was a Qatari national The remaining 21 were non-Qatari donors belonging to various nationalities.

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2006.2.9
2006-11-01
2024-03-29
Loading full text...

Full text loading...

References

  1. Poiesz BJ, Poiesz MJ, Choi D. The human T- cell lymphoma/leukemia viruses. Cancer Invest. 2003; 1::253277.
    [Google Scholar]
  2. Taylor GP. The epidemiology of HTLV-1 in Europe. J Acquired Immune Def. Syndrome Human Retroviro. 1996; 13:Suppl. 1:814.
    [Google Scholar]
  3. The HTLV European Research Network. Seroepidemiology of human T- cell leukemia/ lymphoma viruses in Europe. J Acquired Immune Def. Syndrome Human Retrovirol. 1996; 13:1:6877.
    [Google Scholar]
  4. Hale A, Leung T, Sivasubramaniam S, Kenny J, Sutherland S. Prevalence of antibodies to HTLV in antenatal clinic attenders in Southeast London. J Medical Virology. 52:3:326329.
    [Google Scholar]
  5. Zanetti AR, Zehender G, Tanzi E, Galli C, et al., HTLV-1 I among Italian drug users and hemophilics. Eur J Epidemiol. 1992; 8:5:702707.
    [Google Scholar]
  6. Kleinman S, Swanson P, Allain JP, Lee H. Transfusion transmission of human T- lymphotropic virus type I and II: Serologic and polymerase chain reaction results in recipients identified through look - back investigation. Transfusion. 1993; 33:1:1418.
    [Google Scholar]
  7. Sullivan MT, Williams AE, Fang CT, Grandinetti T, Poiesz BJ, Ehrlich GD. The American Red Cross HTLV-1 /II Collaborative Study Group. (1991) Transmission of human T- lymphotropic virus type I and II by blood transfusion. A retrospective study of recipients of blood components (1983-1988).
  8. Prati D, Capelli C, Rebulla P, Mozzi F, et al., The current risk of retroviral infections transmitted by transfusion in patients who have undergone multiple transfusions. Cooleycare Cooperative Group, Arch Intern Med. 1998; 158:14:15661569.
    [Google Scholar]
  9. And The Retrovirus Epidemiology Donor Study Group, Steven H. Kleinman, Jonathan E. Kaplan, Rima F. Khabbaz, et al., Evaluation of P21E- spiked Western Blot (Immunoblot) in Confirming Human T- Cell Lymphotropic Virus Type I or II Infection in Volunteer Blood Donors. Journal of Clinical Microbiology. 1994; 32:3:603607.
    [Google Scholar]
  10. Public Health Service Working Group. Licensure of screening tests for antibodies to human T- lymphotropic virus type 1. Morbid Mortal Weekly Rep. 1988; 37::736740, 745-747.
    [Google Scholar]
  11. Rios M, Khabbaz RFt, Kaplan JE, Hall Kessler D, Bianco C. Transmission of human T-cell lymphotropic virus (HTLV) type II by transfusion of HTLV-1 screened blood products. J Infect Dis. 1994; 170:1:206210.
    [Google Scholar]
  12. Brennan M, Runganga J, Barbara J A, Contreras M, et al., Prevalence of antibodies to human T cell leukemia/ lymphoma virus in blood donors in north London. BMJ. 1994; 307:6914:12351239.
    [Google Scholar]
  13. Dickmeiss E, Christiansen AH, Smith E. Screening of Donor blood for viral markers, Anti- HIV, HbsAg and HTLV-I/ II in Denmark 1990-1999. Ugeskr Laeger. 2001; 16:19:26232628.
    [Google Scholar]
  14. Khabbaz RF, Onorato IM, Cannon RO, Hartley TM, Roberto B, Hosein B, Kaplan JE. Seroprevalence of HTLV-1 and 2 among intravenous drug users and persons in clinics for sexually transmitted diseases. N Engl J Med. 1992; 326:6:375380.
    [Google Scholar]
  15. Lowis GW, Sheremata WA, Wickman PR, Dube K, Poiesz BJ. HTLV-II- risk factors in Native Americans in Florida. Neuroepidemiology. 1999; 18:1:3747.
    [Google Scholar]
  16. Leon-Ponte M, Noya O, Bianco N, Echeverria de Perez G. Highly endemic human T- lymphotropic virus type II (HTLV-II) Infection In A Venezuelan Guahibo Amerindian group. J Acquired Immune Def. Syndrome Human Retrovirol. 1996; 13:3:281286.
    [Google Scholar]
  17. Bousaz MB, Zapiola I, Quiruelas S, Govrvein D, et al., HTLV Type I and HTLV type II infection among Indian natives from Argentina. AIDS Res Hum Retroviruses. 1994; 10:11:15671571.
    [Google Scholar]
  18. Levine PH, Jacobson S, Elliott R, Cavallero A, et al., HTLV-II infection in Florida Indians. AIDS Res Hum Rertroviruses. 1993; 9:2:123125.
    [Google Scholar]
  19. Bernvil SS, Andrews V, Coulter N. International forum: Saudi Arabia. Donor screening for HTLV-I in Saudi Arabia, is it cost effective? Transfusion Sci. 1997; 18:1:4547.
    [Google Scholar]
  20. El Hazmi MM. Prevalence ofHBV, HCV, HIV-I&2, HTLV-I/II infections among blood donors in a teaching hospital in the Central Region of Saudi Arabia. Saudi Med J. 25:1:2633.
    [Google Scholar]
  21. Naman R, Klayme S, Naboulsi M, Mokhbat J, Jradi O, Ramia S. HTLV-I and HTLV-II infections in volunteer donors and high-risk groups in Lebanon. J Infec. 2002; 45:1:2931.
    [Google Scholar]
  22. Babu PG, Ishida T, Nesadoss J, John TJ. Prevalence of HTLV-I/II antibodies in HIV seropositive and HIV seronegative STD patients in Vellore region in southern India. Scand J Infect. Dis. 1995; 27:2:105108.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2006.2.9
Loading

Most Cited Most Cited RSS feed